ArticleProblemy endokrinologii2026
[Differentiated thyroid carcinoma in children and adolescents].
Article in Problemy endokrinologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThyroid nodules in children are relatively rare; the risk of malignancy is considerably higher compared to adults. The optimal extent of surgery, the indications for radioactive iodine therapy (RAI), and the role of molecular genetic testing in children with thyroid carcinoma remain a matter of debate.
aimTo investigate the clinical course of differentiated thyroid carcinoma (DTC) in children, as well as the outcomes of surgical and combined treatment based on ten years clinical experience at the Endocrinology Research Centre. MATERIALS AND
methodsThis retrospective single-center study included 980 pediatric and adolescent patients who underwent surgery for thyroid nodules between 2015 and 2024. The diagnostic protocol comprised history taking, physical examination, thyroid ultrasound, fine-needle aspiration biopsy, and postoperative histopathological evaluation. Molecular genetic testing was performed in children with a family history or suspected syndromic forms of thyroid carcinoma. The median follow-up duration for patients with DTC was 12 months [1.0; 36.0].
resultsMalignant thyroid tumors were identified in 506 patients (51.6%), the majority of them - differentiated thyroid carcinoma (DTC) (n=472). The most common histological type was papillary thyroid carcinoma (n=448; 88,5%). Metastatic involvement of regional lymph nodes was present in 21% of children. Adjuvant RAI was performed in 48.5% of patients; distant metastases to the lungs were detected in 5.7% of cases. Recurrences were registered in 5.1% of children; in 16.5% of children the disease persisted after primary treatment in the form of biochemical and/or structural persistence. MGI was performed in 66 children; pathogenic variants were detected in 53.1%, most frequently in the DICER1, PTEN, and APC genes.
conclusionDifferentiated thyroid carcinoma in children is characterized by a number of clinical and molecular genetic features, which determines the need for a specialized multidisciplinary approach to their management. The high risk of malignancy in nodules, frequent regional dissemination and peculiarities of the molecular profile argue for the necessity of early diagnosis, integration of molecular testing and personalized choice of the volume of surgical intervention in the conditions of specialized centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.